Results: A total of 238 trials were reviewed and 207 were eligible for inclusion in this study. The primary endpoint of phase III trials shifted significantly from median survival in [1980] [1981] [1982] [1983] [1984] [1985] [1986] [1987] [1988] [1989] [1990] Lastly, the period before 1990 was the only time in which studies were reported as negative due to insufficient magnitude of median survival benefit despite statistical significance.
Conclusion:
A significant shift has occurred over the past 3 decades in the design and interpretation of phase III trials in advanced NSCLC. The use of median survival as the primary measure of benefit is declining alongside the magnitude of benefit deemed clinically relevant. This suggests a shift in the oncology community towards an increasing willingness to accept lesser benefit from new treatments.
